News Sentiment

AAPG sentiment intelligence

Ascentage Pharma Group International news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 57 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 19.97 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

78/100 classification confidence.

Company focus 49

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

+7.9% over one week, +13.5% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Ascentage Pharma (AAPG) Edges Higher, Testing Key Resistance Zone - Trend Reversal Picks

Market Reaction

Price moving ahead of tone

64/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 78/100 classification
One-week reaction 7.9% Price confirming higher
Trend fit Trend inactive 13.5% over four weeks
Fair value -27.9% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 12
Neutral 44
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 49
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
TradingView 13
Market source 9
GlobeNewswire 5
TradingKey 4
Stock Titan 4
The Globe and Mail 3
Zacks Investment Research 2
simplywall.st 2

Event Lens

What the news is about

Classified themes
Market update 29
Earnings 17
Analyst action 4
Guidance 4
Regulatory and legal 1
Macro sensitivity 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-57 of 57
Stock Titan Direct company coverage

[6-K] ASCENTAGE PHARMA GROUP INTERNATIONAL Current Report (Foreign Issuer) | AAPG SEC Filing - Form 6-K

Ascentage Pharma Group International announced that the trustee of its 2022 Restricted Share Unit (RSU) Scheme purchased 190,000 existing shares on the market on June 10, 2026. These shares, representing approximately 0.0509% of the company's issued capital, were acquired for HK$

Tone
Neutral 50/100
Event
Market update
Published
10 Jun 2026 23:40
Source
Stock Titan
The Globe and Mail Direct company coverage

Guotai Haitong Remains a Buy on Ascentage Pharma Group International (6855)

Guotai Haitong has maintained a Buy rating on Ascentage Pharma Group International (6855) with a price target of HK$59.09. The company has a Strong Buy analyst consensus with a target of HK$73.10. Ascentage Pharma reported quarterly revenue of HK$334.74 million and a GAAP net los

Tone
Neutral 50/100
Event
Analyst action
Published
06 Jun 2026 03:09
Source
The Globe and Mail
Market source Direct company coverage

Ascentage Pharma (AAPG) Reports Phase 1b Olverembatinib Data

Ascentage Pharma (AAPG) announced positive Phase 1b results for olverembatinib in lymphoid blast phase chronic myeloid leukemia or Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia, with 91% of patients achieving complete response. The company also pr

Tone
Positive 70/100
Event
Earnings
Published
05 Jun 2026 21:03
Source
Market source